GUARDANT HEALTH INC
NASDAQ: GH (Guardant Health, Inc.)
最近更新时间: 昨天, 10:02PM31.67
0.54 (1.73%)
| 前收盘价格 | 31.13 |
| 收盘价格 | 30.69 |
| 成交量 | 2,088,660 |
| 平均成交量 (3个月) | 1,770,053 |
| 市值 | 3,912,986,880 |
| 价格/销量 (P/S) | 5.67 |
| 股市价格/股市净资产 (P/B) | 55.67 |
| 52周波幅 | |
| 利润日期 | 20 Feb 2025 - 24 Feb 2025 |
| 营业毛利率 | -74.02% |
| 营业利益率 (TTM) | -61.10% |
| 稀释每股收益 (EPS TTM) | -4.28 |
| 季度收入增长率 (YOY) | 33.90% |
| 流动比率 (MRQ) | 6.22 |
| 营业现金流 (OCF TTM) | -254.07 M |
| 杠杆自由现金流 (LFCF TTM) | -151.07 M |
| 资产报酬率 (ROA TTM) | -16.08% |
| 股东权益报酬率 (ROE TTM) | -609.28% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 混合的 | 混合的 |
| Diagnostics & Research (全球的) | 混合的 | 混合的 | |
| 股票 | Guardant Health, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | -1.13 |
|
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Growth |
| 内部持股比例 | 4.57% |
| 机构持股比例 | 105.64% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Cadian Capital Management, Lp | 30 Sep 2024 | 6,930,474 |
| Parkwood Llc | 30 Sep 2024 | 2,800,000 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 50.00 (JP Morgan, 57.88%) | 购买 |
| 50.00 (Leerink Partners, 57.88%) | 购买 | |
| 中 | 43.00 (35.78%) | |
| 低 | 35.00 (Bernstein, 10.52%) | 购买 |
| 平均值 | 42.75 (34.99%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 25.23 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Goldman Sachs | 07 Nov 2024 | 36.00 (13.67%) | 购买 | 28.59 |
| JP Morgan | 07 Nov 2024 | 50.00 (57.88%) | 购买 | 28.59 |
| Bernstein | 30 Oct 2024 | 35.00 (10.51%) | 购买 | 23.07 |
| Leerink Partners | 17 Oct 2024 | 50.00 (57.88%) | 购买 | 20.68 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合